New drug BL-M17D1 enters human testing for hard-to-treat breast cancers
NCT ID NCT06503783
First seen Jan 31, 2026 · Last updated May 22, 2026 · Updated 23 times
Summary
This early-phase study tests a new drug called BL-M17D1 in about 20 adults with advanced breast cancer (HER2-positive or negative) or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants must have tried standard treatments or have no good options left.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, China
Contact
Conditions
Explore the condition pages connected to this study.